Adrenals Contribute to Growth of Castration-Resistant VCaP Prostate Cancer Xenografts.

[1]  T. Laajala,et al.  Antiandrogens Reduce Intratumoral Androgen Concentrations and Induce Androgen Receptor Expression in Castration-Resistant Prostate Cancer Xenografts. , 2016, The American journal of pathology.

[2]  Maria K. Jaakkola,et al.  ROTS: An R package for reproducibility-optimized statistical testing , 2017, PLoS Comput. Biol..

[3]  N. Corcoran,et al.  Androgen synthesis in prostate cancer: do all roads lead to Rome? , 2017, Nature Reviews Urology.

[4]  Tero Aittokallio,et al.  Optimized design and analysis of preclinical intervention studies in vivo , 2016, Scientific Reports.

[5]  K. Storbeck,et al.  11-Ketotestosterone and 11-Ketodihydrotestosterone in Castration Resistant Prostate Cancer: Potent Androgens Which Can No Longer Be Ignored , 2016, PloS one.

[6]  P. Black,et al.  Chemical vs Surgical ADT in Metastatic Prostate Cancer: A Comparison of Side Effects. Commentary on Comparison of Gonadotropin-releasing Hormone Agonists and Orchiectomy: Effects of Androgen Deprivation Therapy. , 2016, Urology.

[7]  T. Choueiri,et al.  Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy: Effects of Androgen-Deprivation Therapy. , 2016, JAMA oncology.

[8]  J. D. de Bono,et al.  Chemical or Surgical Castration--Is This Still an Important Question? , 2016, JAMA oncology.

[9]  M. Milowsky,et al.  Androgen receptor targeting drugs in castration‐resistant prostate cancer and mechanisms of resistance , 2015, Clinical pharmacology and therapeutics.

[10]  M. Nilsson,et al.  Measurement of a Comprehensive Sex Steroid Profile in Rodent Serum by High-Sensitive Gas Chromatography-Tandem Mass Spectrometry. , 2015, Endocrinology.

[11]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[12]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[13]  P. Troncoso,et al.  Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer. , 2015, European urology.

[14]  T. Laajala,et al.  Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model. , 2014, The American journal of pathology.

[15]  F. Saad,et al.  Enzalutamide in metastatic prostate cancer before chemotherapy. , 2014, The New England journal of medicine.

[16]  S. Balk,et al.  Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis , 2014, Oncogene.

[17]  S. Plymate,et al.  The Link Between Androgen Receptor Splice Variants and Castration-Resistant Prostate Cancer , 2014, Hormones and Cancer.

[18]  Wei Shi,et al.  featureCounts: an efficient general purpose program for assigning sequence reads to genomic features , 2013, Bioinform..

[19]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[20]  D. Zheng,et al.  Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade , 2013, Cell.

[21]  Y. Homma,et al.  Intratumoral conversion of adrenal androgen precursors drives androgen receptor‐activated cell growth in prostate cancer more potently than de novo steroidogenesis , 2013, The Prostate.

[22]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[23]  T. Oyama,et al.  Luteinizing hormone (LH)-releasing hormone agonist reduces serum adrenal androgen levels in prostate cancer patients: implications for the effect of LH on the adrenal glands. , 2012, Journal of andrology.

[24]  Kurt Miller,et al.  Increased survival with enzalutamide in prostate cancer after chemotherapy. , 2012, The New England journal of medicine.

[25]  Jukka Corander,et al.  Improved Statistical Modeling of Tumor Growth and Treatment Effect in Preclinical Animal Studies with Highly Heterogeneous Responses In Vivo , 2012, Clinical Cancer Research.

[26]  西井 昌弘.  Luteinizing hormone (LH)-releasing hormone agonist reduces serum adrenal androgen levels in prostate cancer patients : implications for the effect of LH on the adrenal glands , 2012 .

[27]  P. Nelson,et al.  Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. , 2011, Cancer research.

[28]  R. Auchus,et al.  "Getting From Here to There"-Mechanisms and Limitations to the Activation of the Androgen Receptor in Castration-Resistant Prostate Cancer , 2010, Journal of Investigative Medicine.

[29]  P. Nelson,et al.  Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. , 2010, The Journal of clinical investigation.

[30]  R. Auchus,et al.  3beta-hydroxysteroid dehydrogenase is a possible pharmacological target in the treatment of castration-resistant prostate cancer. , 2010, Endocrinology.

[31]  K. Knudsen,et al.  Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancer , 2010, Trends in Endocrinology & Metabolism.

[32]  J. Humm,et al.  Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study , 2010, The Lancet.

[33]  G. Jenster,et al.  Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. , 2010, Cancer research.

[34]  Mark D. Robinson,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[35]  M. Gleave,et al.  Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts , 2009, The Journal of Steroid Biochemistry and Molecular Biology.

[36]  Shafiq A. Khan,et al.  Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol , 2008, Molecular and Cellular Endocrinology.

[37]  Mitch Dowsett,et al.  Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  M. Gleave,et al.  Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. , 2008, Cancer research.

[39]  T. Golub,et al.  Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. , 2006, Cancer research.

[40]  Duane D. Miller,et al.  Structural basis for antagonism and resistance of bicalutamide in prostate cancer , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[41]  T. Ratliff.  Molecular Determinants of Resistance to Antiandrogen Therapy , 2004 .

[42]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[43]  I Judson,et al.  Hormonal impact of the 17α-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer , 2004, British Journal of Cancer.

[44]  C. Heinlein,et al.  Androgen receptor in prostate cancer. , 2004, Endocrine reviews.

[45]  K. Sugimachi,et al.  Effect of glucocorticoid deficiency after adrenalectomy on antitumor immunity , 2004, Cancer Immunology, Immunotherapy.

[46]  Chawnshang Chang,et al.  Expression and Degradation of Androgen Receptor: Mechanism and Clinical Implication , 2003 .

[47]  K. Pienta,et al.  VCaP, a cell-based model system of human prostate cancer. , 2001, In vivo.

[48]  Allan J. SymsS,et al.  Mechanism of Androgen-receptor Augmentation , 2001 .

[49]  W. V. van Weerden,et al.  Use of nude mouse xenograft models in prostate cancer research , 2000, The Prostate.

[50]  Donna M. Peehl,et al.  Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor , 2000, Nature Medicine.

[51]  W. Wetsel,et al.  Effects of Castration and Chronic Steroid Treatments on Hypothalamic Gonadotropin-Releasing Hormone Content and Pituitary Gonadotropins in Male Wild-Type and Estrogen Receptor-α Knockout Mice. , 1998, Endocrinology.

[52]  G. Bubley,et al.  Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[53]  J Isola,et al.  Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. , 1997, Cancer research.

[54]  K. Pettersson,et al.  One-step all-in-one dry reagent immunoassays with fluorescent europium chelate label and time-resolved fluorometry. , 1996, Clinical chemistry.

[55]  G. Bubley,et al.  Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. , 1995, The New England journal of medicine.

[56]  H. Klocker,et al.  Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. , 1993, Molecular endocrinology.

[57]  M. Resnick,et al.  Xenografts of primary human prostatic carcinoma. , 1993, Journal of the National Cancer Institute.

[58]  F. Schröder,et al.  Adrenal glands of mouse and rat do not synthesize androgens. , 1992, Life sciences.

[59]  F. Labrie.  Intracrinology , 1991, Molecular and Cellular Endocrinology.

[60]  T. H. van der Kwast,et al.  Androgen receptors in endocrine‐therapy‐resistant human prostate cancer , 1991, International journal of cancer.

[61]  D. Russell,et al.  Structural and biochemical properties of cloned and expressed human and rat steroid 5 alpha-reductases. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[62]  R. Hampl,et al.  Steroid and Steroid Regulating Hormones in Human Male Castrates , 1988, Experimental and clinical endocrinology.

[63]  J. Norris,et al.  Mechanism of androgen-receptor augmentation. Analysis of receptor synthesis and degradation by the density-shift technique. , 1985, The Journal of biological chemistry.